Literature DB >> 15638785

Role of vascular nitric oxide in experimental liver cirrhosis.

Noemí M Atucha1, F Javi A Nadal, David Iyú, Antonia Alcaraz, Alicia Rodríguez-Barbero, M Clara Ortiz, José Miguel López-Novoa, Joaquín García-Estañ.   

Abstract

One of the most important features of liver cirrhosis is the splanchnic and systemic arterial vasodilation, related to an increase in vascular capacity and an active vasodilation. This arterial vasodilation seems to be the consequence of the excessive generation of vasodilating substances, which also contributes to a lower than normal pressor response to circulating nervous or humoral substances. The following review analyzes the mechanisms responsible for the vascular hyporesponse to vasoconstrictors observed in the experimental models of liver cirrhosis. It has become increasingly clear that, among the great variety of substances studied, nitric oxide (NO) seems to be one of the main contributors to this vascular alteration, since elimination of the endothelium or inhibition of its synthesis corrects it. The mechanism by which NO interferes with the contractile apparatus in smooth muscle cells seems to be related to a direct effect on calcium entry from the extracellular space and release from the internal stores.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15638785     DOI: 10.2174/1570161052773889

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  3 in total

1.  A novel liver-targeted nitric oxide donor UDCA-Thr-NO protects against cirrhosis and portal hypertension.

Authors:  Jialin Sun; Menghua Li; Shiyong Fan; Zhongwu Guo; Bohua Zhong; Xueyuan Jin; Weiguo Shi
Journal:  Am J Transl Res       Date:  2018-02-15       Impact factor: 4.060

2.  PDEs1-5 activity and expression in tissues of cirrhotic rats reveal a role for aortic PDE3 in NO desensitization.

Authors:  Rima Tahseldar-Roumieh; Thérèse Keravis; Suha Maarouf; Hélène Justiniano; Ramzi Sabra; Claire Lugnier
Journal:  Int J Exp Pathol       Date:  2009-09-15       Impact factor: 1.925

3.  The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma.

Authors:  Atsushi Kawamura; Haruki Uojima; Makoto Chuma; Xue Shao; Hisashi Hidaka; Takahide Nakazawa; Akira Take; Yoshihiko Sakaguchi; Kazushi Numata; Makoto Kako; Akito Nozaki; Shintaro Azuma; Kazue Horio; Chika Kusano; Koichiro Atsuda
Journal:  BMC Cancer       Date:  2022-08-23       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.